Triple threat: new combo aims to tackle Hard-to-Treat prostate cancer

NCT ID NCT07226986

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug, AMO959, combined with a targeted radiation therapy (Pluvicto) and a hormone therapy in men with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has stopped responding to prior hormone treatment. The trial has two phases: first to check safety and dosing, then to see if the combo can lower PSA levels. About 123 men will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AMO959 (a DNA damage repair blocker) combined with Pluvicto (a targeted radiation drug) and a hormone therapy (enzalutamide or abiraterone)

What this could lead to

If successful, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.

What could go wrong

This is an early-phase trial (Phase 1/2) with only 123 participants, so safety and effectiveness are not yet proven. The combination may cause significant side effects or fail to improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSMA-POSITIVE METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WITH PRIOR EXPOSURE TO ONE PRIOR ARPI WHO ARE CANDIDATES FOR TAXANE-BASED CHEMOTHERAPY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Novartis Investigative Site
RECRUITING

Malvern, Victoria, 3144, Australia
Novartis Investigative Site
RECRUITING

Melbourne, Victoria, 3004, Australia
Novartis Investigative Site
RECRUITING

Murdoch, Western Australia, 6150, Australia
Novartis Investigative Site
RECRUITING

Bordeaux, 33076, France
Novartis Investigative Site
RECRUITING

Clermont-Ferrand, 63011, France
Novartis Investigative Site
RECRUITING

Nantes, 44093, France
Novartis Investigative Site
RECRUITING

Villejuif, 94800, France
Novartis Investigative Site
RECRUITING

Dresden, Saxony, 01307, Germany
Novartis Investigative Site
RECRUITING

Essen, 45147, Germany
Novartis Investigative Site
RECRUITING

München, 80377, Germany
Novartis Investigative Site
RECRUITING

Cona, FE, 44124, Italy
Novartis Investigative Site
RECRUITING

Milan, MI, 20133, Italy
Novartis Investigative Site
RECRUITING

Naples, 80131, Italy
Novartis Investigative Site
RECRUITING

Sapporo, Hokkaido, 060-8648, Japan
Novartis Investigative Site
RECRUITING

Granada, Andalusia, 18014, Spain
Novartis Investigative Site
RECRUITING

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site
RECRUITING

Barcelona, 08036, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28041, Spain
Rio Grande Urology
RECRUITING

El Paso, Texas, 79912, United States

Contact

Contact Email: •••••@•••••
Utah Intermountain Medical Center
RECRUITING

Murray, Utah, 84107, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••